AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Business

Skeptical Investors Should Take Another Look at AbbVie

Investors have been skeptical about AbbVie lately, particularly after last week’s second-quarter financial report. That doesn’t make all that much sense, given that the company reported net revenues of $8.278 billion for the quarter.

July 30, 2018

3 min read

Mark Terry

Business

Alector Closes $133 Million to Expand Alzheimer’s Programs

South San Francisco-based Alector closed on a Series E financing worth $133 million. The money will be used to advance the company’s clinical programs and expand its discovery platform.

July 25, 2018

3 min read

Mark Terry

Drug Development

AbbVie, Neurocrine Snag FDA Approval for Oral Endometriosis Treatment Elagolix

Shares of AbbVie are up slightly this morning after the company announced that it finally received regulatory approval for its endometriosis drug elagolix. The approval marks the first new approved oral treatment for endometriosis-associated pain in more than 10 years.

July 24, 2018

2 min read

Alex Keown

Business

AbbVie Strikes Deal With Mylan to Delay Humira Biosimilar Challenge

AbbVie continues to do what it can to protect its Humira-driven revenue stream. This morning the company inked an agreement to grant Mylan the rights to begin marketing its biosimilar to Humira in the United States in 2023.

July 17, 2018

2 min read

Alex Keown

Business

Dermavant Bags GSK Phase III-Ready Psoriasis Treatment in $330 Million Deal

Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences has returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.

July 12, 2018

2 min read

Alex Keown

Drug Development

AbbVie Stock Drops After Disappointing Clinical Trial Update

AbbVie’s shares dropped about 2.2 percent in premarket trading this morning after releasing an update on its Phase III B-cell lymphoma trial.

July 11, 2018

3 min read

Mark Terry

FDA

Investigation Examines Big Pharma Payments to FDA Advisers

Has the U.S. Food and Drug Administration failed to do its due diligence in finding and reporting financial conflicts of interest between members of its scientific advisory committees and pharmaceutical companies?

July 6, 2018

3 min read

Alex Keown

Biotech Bay

Is Gilead Poised for a Comeback?

Gilead may be down, but at least one analyst thinks the company is poised for a turnaround.

July 6, 2018

3 min read

Mark Terry

Pharm Country

Top 10 Stories of the First Half of 2018

It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.

July 3, 2018

5 min read

Mark Terry

JOBS